Natera(US:NTRA)2021-11-07 09:33Financial Performance - Natera processed 407,000 tests in Q3 2021, a 55% increase compared to Q3 2020[5] - Total revenues for Q3 2021 reached $158 million, representing a 61% growth compared to Q3 2020[5] - Product revenues in Q3 2021 amounted to $151 million, a 62% increase compared to Q3 2020[5] - Natera is raising its revenue guidance from $600-$620 million to $615-$625 million, a $100 million increase from the start of the year[5] - Cash and investments stand at $1,023.9 million as of September 30, 2021, compared to $580.5 million as of June 30, 2021, representing a $443.4 million increase[30] Product Development and Validation - Prospera Kidney demonstrates improved sensitivity with the enhanced algorithm, showing overall sensitivity >99% and specificity 87.5%[17] - The Trifecta Study validates Prospera with Quantification, showing an area under the curve of 0.89 using molecular pathology as truth[18] - Prospera Heart transplant assessment test shows an area under the curve of 0.88 with Quantification[22] - Prospera lung test shows an area under the curve of 0.91 for acute rejection vs stable in the VALID study[23] Oncology - Signatera is selected for NRG Oncology's landmark CIRCULATE-US study[5] - Data validates Signatera velocity metric, showing a 43% 3-year overall survival for patients with fast tumor growth type (137% increase/mo) compared to 100% for slow growth type (27% increase/mo)[27]